Johnson & Johnson (NYSE:JNJ) Announces Earnings Results

Johnson & Johnson (NYSE:JNJ) posted its earnings results on Tuesday. The company reported $2.48 earnings per share for the quarter, topping analysts’ consensus estimates of $2.29 by $0.19, MarketWatch Earnings reports. The company had revenue of $23.31 billion during the quarter, compared to analyst estimates of $22.54 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 17.95%. Johnson & Johnson’s revenue was up 27.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.67 earnings per share.

Shares of JNJ opened at $169.49 on Thursday. Johnson & Johnson has a 12 month low of $133.65 and a 12 month high of $173.65. The firm’s fifty day simple moving average is $167.25. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.28. The stock has a market cap of $446.33 billion, a price-to-earnings ratio of 29.95, a PEG ratio of 2.71 and a beta of 0.71.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 7th. Stockholders of record on Tuesday, August 24th will be issued a dividend of $1.06 per share. The ex-dividend date is Monday, August 23rd. This represents a $4.24 annualized dividend and a dividend yield of 2.50%. Johnson & Johnson’s dividend payout ratio is presently 52.80%.

A hedge fund recently bought a new stake in Johnson & Johnson stock. OLD Mission Capital LLC bought a new position in Johnson & Johnson (NYSE:JNJ) in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,432 shares of the company’s stock, valued at approximately $362,000. Institutional investors and hedge funds own 66.60% of the company’s stock.

JNJ has been the subject of a number of analyst reports. Credit Suisse Group set a $193.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, June 7th. Morgan Stanley started coverage on Johnson & Johnson in a report on Friday, May 28th. They set an “overweight” rating and a $187.00 target price for the company. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $190.38.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More: What is a Swap?

Earnings History for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.